Immunotherapy in Non-Muscle Invasive Bladder Cancer: Expert Takeaways From Berlin 2025

20 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join us for an expert discussion on the evolving role of immunotherapy in non–muscle invasive bladder cancer (NMIBC). Discover the rationale behind immunotherapy-based strategies for high-risk NMIBC and explore how novel treatment approaches could reshape the therapeutic landscape.

Our panel will review the latest clinical data from ESMO 2025 and examine how these findings may influence future clinical practice. This live session will provide valuable insights into the latest research and practical implications for managing patients with NMIBC, helping clinicians stay current in this advancing field.

Faculty:
Maria De Santis, MD
Professor of Translational GU-Oncology
Department of Urology
Charité Universitätsmedizin Berlin
Berlin, Germany

Faculty:
Neal D. Shore, MD, FACS
Director, START Carolinas/Carolina Urologic Research Center
Head, GU Oncology START Research
Myrtle Beach, South Carolina, United States

Earn free 0.50 AMA PRA Category 1 Credit™. Access for credit will be shared at the end of this live event.

Click the link to view the Accreditation and Disclosure details before participating: https://www.medscape.org/s/viewarticle/immunotherapy-nmibc-expert-takeaways-berlin-2025-2025a1000zsq

Supported by an independent educational grant from AstraZeneca.
Categoria
Oncology
Commenta per primo questo video.

Prossimo